Premium
P2‐255: The retina as a window to monitor Alzheimer's disease in human and rodent models: In vivo imaging of retinal Aβ plaques for immunotherapy assessment
Author(s) -
Koronyo Yosef,
Salumbides Brenda,
Sheyn Julia,
Fuchs Sebastien,
Cohen Robert,
Miller Carol,
Black Keith,
KoronyoHamaoui Maya
Publication year - 2012
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2012.05.963
Subject(s) - microglia , pathology , retinal , retina , immunotherapy , in vivo , medicine , ex vivo , immune system , retinal degeneration , genetically modified mouse , preclinical imaging , transgene , inflammation , biology , immunology , neuroscience , ophthalmology , biochemistry , microbiology and biotechnology , gene
a significantly lower Glu/Cr ratio was observed in AD (0.49 6 0.04) compared to CN (0.596 0.03, p<0.05). Meanwhile, the NAA/Cr ratio was significantly lower (ps<0.001) in AD than in CN in both the PCG (D1⁄4 0.126 0.02) and the DLPFC (D 1⁄4 0.18 6 0.03). Using solely the absolute metabolite levels of Cr, NAA, and Glu in the DLPFC, the accuracy for the identification of individuals with early AD (vs. CN) reached 0.84 (95% CI 1⁄4 0.74-0.93). Conclusions: An increased Cr concentration in PCG may be associated with the development of AD, reflecting the underlying neurodegenerative pathology and the disturbed balance of energy supply and energy demand. The study also suggests that combining information on changes of Cr levels and those of other major metabolites can help improve AD identification.